Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marijke Hyke Algera

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Iscience|May 1, 2023
A biomarker of opioid-induced respiratory toxicity in experimental studiesMarieke Hellinga, Marijke Hyke Algera, Rutger van der Schrier, et al.
British Journal of Anaesthesia|March 28, 2019
Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversalMarijke Hyke Algera, Jasper Kamp, Rutger van der Schrier, et al.
Clinical Pharmacology and Therapeutics|February 6, 2023
Oral Oxycodone-Induced Respiratory Depression During Normocapnia and Hypercapnia: A Pharmacokinetic-Pharmacodynamic Modeling StudyMarieke Hellinga, Marijke Hyke Algera, Erik Olofsen, et al.
Annals of Palliative Medicine|December 24, 2019
Opioid utility function: methods and implicationsCornelis Jan van Dam, Marijke Hyke Algera, Erik Olofsen, et al.
JCI Insight|March 22, 2022
Modeling buprenorphine reduction of fentanyl-induced respiratory depressionErik Olofsen, Marijke Hyke Algera, Laurence Moss, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve IndividualsMarijke Hyke Algera, Erik Olofsen, Laurence Moss, et al.
Plos One|January 27, 2022
Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patientsLaurence M Moss, Marijke Hyke Algera, Robert Dobbins, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Iscience|May 1, 2023
A biomarker of opioid-induced respiratory toxicity in experimental studiesMarieke Hellinga, Marijke Hyke Algera, Rutger van der Schrier, et al.
British Journal of Anaesthesia|March 28, 2019
Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversalMarijke Hyke Algera, Jasper Kamp, Rutger van der Schrier, et al.
Clinical Pharmacology and Therapeutics|February 6, 2023
Oral Oxycodone-Induced Respiratory Depression During Normocapnia and Hypercapnia: A Pharmacokinetic-Pharmacodynamic Modeling StudyMarieke Hellinga, Marijke Hyke Algera, Erik Olofsen, et al.
Annals of Palliative Medicine|December 24, 2019
Opioid utility function: methods and implicationsCornelis Jan van Dam, Marijke Hyke Algera, Erik Olofsen, et al.
JCI Insight|March 22, 2022
Modeling buprenorphine reduction of fentanyl-induced respiratory depressionErik Olofsen, Marijke Hyke Algera, Laurence Moss, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve IndividualsMarijke Hyke Algera, Erik Olofsen, Laurence Moss, et al.
Plos One|January 27, 2022
Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patientsLaurence M Moss, Marijke Hyke Algera, Robert Dobbins, et al.
Pageof 1